Biomarkers in Lung Cancer Screening
April 23, 2019 | Online

Overview

This one hour program will feature three presentations and provide ample time for questions and discussion.

Dr. Pierre Massion will provide a background for the need for biomarkers to facilitate risk assessment during lung cancer screening, including the risk of developing the disease and the risk of having the disease.  He will discuss a standard process for biomarker validation and describe a possible pragmatic approach to testing for clinical utility.

Dr. Chris Amos will describe how genetic factors interact with environmental exposures to increase the risk for cancer and their impact on treatment strategies. Results are presented from large genetic studies of family and population based studies that have identified selected high risk factors and many lower risk genetic factors that contribute to risk for lung cancer, along with smoking.  He will also discuss the use of genetic factors to show that increased BMI, longer telomere length and higher levels of vitamin B12 contribute to lung cancer risk.

In the concluding presentation, Dr. Luis Montuenga will summarize the discovery and developmental status of currently promising molecular candidates, such as autoantibodies, microRNAs, circulating tumor DNA, blood protein profiling, etc. Other emerging technologies to be followed closely, such as exhaled breath biomarkers, metabolomics, sputum cell imaging, next generation sequencing in circulating tumor DNA, will be mentioned.  The importance of the integration of different molecular technologies together with imaging radiomics and artificial intelligence will be addressed.  Looking forward, the main challenges to new discovery strategies will be described with a focus on the most promising avenues in the field of biomarkers in the context of lung cancer screening.

What you should expect to learn

After viewing this webinar, attendees will be able to:

  • Understand the need for biomarkers in assessing the risk for lung cancer;
  • Describe new strategies for the validation and utility testing of candidate biomarkers in the clinical setting;
  • Identify genes that greatly increase risk for lung cancer when mutated;
  • Characterize the role of lower-risk genetic factors for understanding etiology of lung cancer;
  • Evaluate the impact that selected host factors such as BMI and telomere length have on lung cancer risk;
  • Provide an update of the main biomarker candidates in the field of screening both for risk assessment and indeterminate nodule characterization;
  • Distinguish the levels of validation reached by the most relevant candidates that have been proposed /published in the recent past;
  • Describe the importance of integration of technologies.

Contact

Member Experience Department